Stevens-Johnson syndrome and toxic epidermal necrolysis: Difference between revisions
m (Rossdonaldson1 moved page Stevens Johnson Syndrome and Toxic Epidermal Necrolysis to Stevens-Johnson syndrome and toxic epidermal necrolysis) |
(Text replacement - "BSA" to "BSA") |
||
(27 intermediate revisions by 9 users not shown) | |||
Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*SJS and TEN exist on a spectrum of disease | *SJS and TEN exist on a spectrum of disease | ||
**SJS involves <10% of BSA | **SJS involves <10% of [[BSA]] | ||
**TEN involves >30% of BSA | **TEN involves >30% of [[BSA]] | ||
*Dermatologic emergency | *Dermatologic emergency | ||
* | |||
** | ===Causes=== | ||
**Malignancy - lymphoma | *Drugs | ||
**The most common cause overall<ref>Mockenhaupt M (2011). "The current understanding of Stevens–Johnson syndrome and toxic epidermal necrolysis". Expert Review of Clinical Immunology 7 (6): 803–15. doi:10.1586/eci.11.66. PMID 22014021</ref> | |||
**Infectious | **Many have been linked. Common offensive agents include: sulfa, quinolones, PCN, ASA, acetaminophen, carbamazepine, NSAIDs, [[phenytoin]], corticosteroids, immunizations | ||
**High dose or rapid loading of allopurinol<ref>Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008 Jan. 58(1):25-32. [Medline]</ref>, lamotrigine<ref>Schlienger RG, Shapiro LE, Shear NH. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia. 1998. 39 Suppl 7:S22-6. [Medline]</ref> | |||
*Malignancy - lymphoma, brain tumor treated with radiotherapy and antiepileptics<ref>[http://emedicine.medscape.com/article/1197450-overview#a4 Medscape: Stevens-Johnson Syndrome]</ref> | |||
*Idiopathic | |||
*Immunosuppression - [[HIV]] <ref>Rotunda A, Hirsch RJ, Scheinfeld N, Weinberg JM. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol. 2003. 83(1):1-9. [Medline]</ref> | |||
*Infectious | |||
*Autoimmune- SLE<ref>Horne NS, Narayan AR, Young RM, Frieri M. Toxic epidermal necrolysis in systemic lupus erythematosus. Autoimmun Rev. 2006 Feb. 5(2):160-4. [Medline]</ref> | |||
==Clinical Features== | ==Clinical Features== | ||
[[File:Stevens-johnson-syndrome.jpg|thumbnail|Stevens–Johnson syndrome]] | [[File:Stevens-johnson-syndrome.jpg|thumbnail|Stevens–Johnson syndrome]] | ||
[[File:SJS.jpg|thumbnail|Mucosal lesions with Stevens-Johnson]] | [[File:SJS.jpg|thumbnail|Mucosal lesions with Stevens-Johnson]] | ||
*Often have prodrome (fever, URI symptoms, | *Often have prodrome (fever, URI symptoms, headache, malaise) | ||
*Macular rash | *Macular rash | ||
**+/- Target lesions | **+/- Target lesions | ||
Line 22: | Line 28: | ||
**Eye involvement can be severe | **Eye involvement can be severe | ||
*In severe cases, respiratory tract and GI involvement may occur | *In severe cases, respiratory tract and GI involvement may occur | ||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
*[[Erythema Multiforme]] | *[[Erythema Multiforme]] | ||
*[[ | *[[Staphylococcal scalded skin syndrome]] | ||
*[[Erythroderma]] | *[[Erythroderma]] | ||
*[[Toxic Shock Syndrome]] | *[[Toxic Shock Syndrome]] | ||
*[[Drug eruption]] | *[[Drug eruption]] | ||
*[[Acute generalized exanthematous pustulosis]] | |||
*[[DRESS syndrome]] | |||
{{DDX oral rashes and lesions}} | |||
==Evaluation== | |||
===Work-Up=== | |||
*CBC | |||
*CMP | |||
*ESR | |||
*[[CXR]] | |||
*Examine eyes/mucosal surfaces | |||
== | ===Evaluation=== | ||
*Clinical diagnosis | |||
==Management== | |||
*Removal of inciting cause if identified | *Removal of inciting cause if identified | ||
*Fluid replacement - treat shock | *Fluid replacement - treat shock with IV fluids according to burn protocols | ||
*Infection control | *Infection control | ||
*Wound care | *Wound care | ||
*Use of IVIG, plasmapheresis, and corticosteroids are controversial but may be beneficial | *Use of [[IVIG]], [[plasmapheresis]], and [[corticosteroids]] are controversial but may be beneficial | ||
*Evidence that Etanercept (TNF-alpha antagonist) may decrease time to skin healing and mortality compared to IV prednisolone <ref>Wang, C.-W., Yang, L.-Y., Chen, C.-B., Ho, H.-C., Hung, S.-I., Yang, C.-H., … and the Taiwan Severe Cutaneous Adverse Reaction (TSCAR) Consortium. (2018). Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. The Journal of Clinical Investigation, 128(3), 985–996.</ref> | |||
== Disposition | ==Disposition== | ||
*Admit to burn unit or ICU | *Admit to burn unit or ICU | ||
Line 52: | Line 67: | ||
One point for each of the following assessed within 1st 24 hours of admission: | One point for each of the following assessed within 1st 24 hours of admission: | ||
*Age | *Age >/= 40 years (OR 2.7) | ||
*Heart Rate | *Heart Rate >/= 120 beats per minute (OR 2.7) | ||
*Cancer/Hematologic malignancy (OR 4.4) | *Cancer/Hematologic malignancy (OR 4.4) | ||
*Body surface area on day 1 | *Body surface area on day 1; >10% (OR2.9) | ||
*Serum urea level (BUN) | *Serum urea level (BUN) >28mg/dL (>10mmol/L) (OR 2.5) | ||
*Serum bicarbonate | *Serum bicarbonate <20mmol/L (OR 4.3) | ||
*Serum glucose | *Serum glucose > 252mg/dL (>14mmol/L) (OR5.3) | ||
'''Predicted mortality based on above total:''' | '''Predicted mortality based on above total:''' | ||
Score 0-1 | {| {{table}} | ||
| align="center" style="background:#f0f0f0;"|'''Score''' | |||
2 | | align="center" style="background:#f0f0f0;"|'''Mortality''' | ||
|- | |||
3 | | 0-1||3.2% | ||
|- | |||
4 | | 2||12.1% | ||
|- | |||
| 3||35.3% | |||
|- | |||
| 4||58.3% | |||
|- | |||
| 5+||90.0% | |||
|} | |||
==See Also== | |||
*[[Rashes]] | |||
== | ==References== | ||
<References/> | |||
[[Category: | [[Category:Dermatology]] | ||
[[Category:Pharmacology]] | |||
[[Category:Critical Care]] |
Revision as of 07:39, 12 February 2019
Background
- SJS and TEN exist on a spectrum of disease
- Dermatologic emergency
Causes
- Drugs
- Malignancy - lymphoma, brain tumor treated with radiotherapy and antiepileptics[4]
- Idiopathic
- Immunosuppression - HIV [5]
- Infectious
- Autoimmune- SLE[6]
Clinical Features
- Often have prodrome (fever, URI symptoms, headache, malaise)
- Macular rash
- +/- Target lesions
- Usually starts centrally, spreads peripherally, and may become confluent
- May be painful
- May have +Nikolsky sign (denude when touched)
- Mucous membranes can be severely affected
- Eye involvement can be severe
- In severe cases, respiratory tract and GI involvement may occur
Differential Diagnosis
- Erythema Multiforme
- Staphylococcal scalded skin syndrome
- Erythroderma
- Toxic Shock Syndrome
- Drug eruption
- Acute generalized exanthematous pustulosis
- DRESS syndrome
Oral rashes and lesions
- Angioedema
- Aphthous stomatitis
- Herpes gingivostomatitis
- Herpes labialis
- Measles (Koplik's spots)
- Perioral dermatitis
- Oral thrush
- Steven Johnson syndrome
- Streptococcal pharyngitis
- Tongue diagnoses
- Vincent's angina
Evaluation
Work-Up
- CBC
- CMP
- ESR
- CXR
- Examine eyes/mucosal surfaces
Evaluation
- Clinical diagnosis
Management
- Removal of inciting cause if identified
- Fluid replacement - treat shock with IV fluids according to burn protocols
- Infection control
- Wound care
- Use of IVIG, plasmapheresis, and corticosteroids are controversial but may be beneficial
- Evidence that Etanercept (TNF-alpha antagonist) may decrease time to skin healing and mortality compared to IV prednisolone [7]
Disposition
- Admit to burn unit or ICU
Prognosis
Validated with SCORTEN mortality assessment:
One point for each of the following assessed within 1st 24 hours of admission:
- Age >/= 40 years (OR 2.7)
- Heart Rate >/= 120 beats per minute (OR 2.7)
- Cancer/Hematologic malignancy (OR 4.4)
- Body surface area on day 1; >10% (OR2.9)
- Serum urea level (BUN) >28mg/dL (>10mmol/L) (OR 2.5)
- Serum bicarbonate <20mmol/L (OR 4.3)
- Serum glucose > 252mg/dL (>14mmol/L) (OR5.3)
Predicted mortality based on above total:
Score | Mortality |
0-1 | 3.2% |
2 | 12.1% |
3 | 35.3% |
4 | 58.3% |
5+ | 90.0% |
See Also
References
- ↑ Mockenhaupt M (2011). "The current understanding of Stevens–Johnson syndrome and toxic epidermal necrolysis". Expert Review of Clinical Immunology 7 (6): 803–15. doi:10.1586/eci.11.66. PMID 22014021
- ↑ Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008 Jan. 58(1):25-32. [Medline]
- ↑ Schlienger RG, Shapiro LE, Shear NH. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia. 1998. 39 Suppl 7:S22-6. [Medline]
- ↑ Medscape: Stevens-Johnson Syndrome
- ↑ Rotunda A, Hirsch RJ, Scheinfeld N, Weinberg JM. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol. 2003. 83(1):1-9. [Medline]
- ↑ Horne NS, Narayan AR, Young RM, Frieri M. Toxic epidermal necrolysis in systemic lupus erythematosus. Autoimmun Rev. 2006 Feb. 5(2):160-4. [Medline]
- ↑ Wang, C.-W., Yang, L.-Y., Chen, C.-B., Ho, H.-C., Hung, S.-I., Yang, C.-H., … and the Taiwan Severe Cutaneous Adverse Reaction (TSCAR) Consortium. (2018). Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. The Journal of Clinical Investigation, 128(3), 985–996.